The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested the latest economic data and Trump's response to Canada and EU tariffs. The S&P 500 closed in correction territory.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Eli Lilly (LLY) stock dropped by 0.22%, underperforming the S&P 500’s 0.49% gain. Over the past month, the stock has fallen 4 ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking The ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while ...

Eli Lilly revealed major advancements in its alopecia and atopic dermatitis studies, likely driving its 3.77% stock rise. The ...

Now, that account is worth $55,000, with a 65% concentration in Nvidia (NVDA), which was my first stock buy, then a 20% concentration in Novo Nordisk (NVO) and Eli Lilly (LLY) stock, with 15% ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...